Filed Pursuant to Rule 424(b)(3)
File No. 333-199121
PROSPECTUS SUPPLEMENT NO. 6 DATED JUNE 23, 2015 (TO PROSPECTUS
DATED NOVEMBER 18, 2014) AS SUPPLEMENTED BY PROSPECTUS SUPPLEMENT NO. 1 DATED DECEMBER 17, 2014, PROSPECTUS SUPPLEMENT NO. 2 DATED
FEBRUARY 11, 2015, PROSPECTUS SUPPLEMENT NO. 3 DATED MARCH 10, 2015, PROSPECTUS SUPPLEMENT NO. 4 DATED APRIL 7, 2015 AND PROSPECTUS
SUPPLEMENT NO. 5 DATED MAY 14, 2015
APPLIED
DNA SCIENCES, INC.
PROSPECTUS
$9,100,000
OF SHARES OF COMMON STOCK AND
WARRANTS TO PURCHASE SHARES OF COMMON STOCK
This Prospectus Supplement No.6 updates and supplements the
prospectus of Applied DNA Sciences, Inc. (“the “Company”, “we”, “us”, or “our”)
dated November 18, 2014 , as updated and supplemented by Prospectus Supplement No. 1 dated December 17, 2014, Prospectus Supplement
No. 2 dated February 11, 2015, Prospectus Supplement No. 3 dated March 10, 2015, Prospectus Supplement No. 4 dated April 7, 2015
and Prospectus Supplement No. 5 dated May 14, 2015 (collectively, the “Prospectus”), with the following attached documents
which we filed with the Securities and Exchange Commission:
|
A. |
Our Current Report on Form 8-K dated June 16, 2015 filed with the Securities and Exchange Commission on June 18, 2015 |
|
|
|
This Prospectus Supplement No.
6 should be read in conjunction with the Prospectus, which is required to be delivered with this Prospectus Supplement. This Prospectus
Supplement updates, amends and supplements the information included in the Prospectus. If there is any inconsistency between the
information in the Prospectus and this Prospectus Supplement, you should rely on the information in this Prospectus Supplement.
This Prospectus Supplement is not complete
without, and may not be delivered or utilized except in connection with, the Prospectus, including any amendments or supplements
to it.
The purchase of the securities offered
through the Prospectus involves a high degree of risk. Before making any investment in our common stock and/or warrants, you should
carefully consider the risk factors section beginning on page 8 of the Prospectus and the “Risk Factors” section in
our Annual Report on Form 10-K filed with the Securities and Exchange Commission on December 15, 2014, as amended on Form 10-K/A
on March 6, 2015.
You should rely only on the information
contained in the Prospectus, as supplemented or amended by this Prospectus Supplement No. 6 and any other prospectus supplement
or amendment thereto. We have not authorized anyone to provide you with different information.
Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of
the Prospectus and this Prospectus Supplement. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement
No. 6 is June 23, 2015
INDEX
TO FILINGS
|
Annex |
A. The Company’s Current Report on Form 8-K dated June
16, 2015 filed with the Securities and Exchange Commission on June 18, 2015 |
A |
|
|
|
|
Annex A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
June 16, 2015
Applied DNA Sciences, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction
of Incorporation) |
001-36745
(Commission File Number) |
59-2262718
(IRS Employer
Identification No.) |
50 Health Sciences Drive
Stony Brook, New York 11790
(Address of Principal Executive Offices) (Zip
Code)
631-240- 8800
(Registrant’s telephone number, including
area code)
Not Applicable
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2 below):
|
|
|
¨ |
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
|
|
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 5.07. Submission of Matters to
a Vote of Security Holders.
On June 16, 2015 the Company
held its Annual Meeting of Stockholders. The following proposals were voted on and approved by the Company’s stockholders
at the Annual Meeting with the stockholders having voted as set forth below:
Proposal 1 - to elect our board
of directors, consisting of James A. Hayward, John Bitzer, III, Joseph D. Ceccoli, Charles Ryan, Yacov Shamash, and Sanford R.
Simon, each for a one-year term or until their successors are duly elected and qualified:
Directors |
|
For |
|
Withheld |
|
James A. Hayward |
|
8,189,944 |
|
87,553 |
|
|
John Bitzer, III |
|
8,161,501 |
|
115,996 |
|
|
Joseph D. Ceccoli |
|
8,152,695 |
|
124,802 |
|
|
Charles Ryan |
|
8,160,572 |
|
116,925 |
|
|
Yacov Shamash |
|
8,158,377 |
|
119,120 |
|
|
Sanford R. Simon |
|
8,184,517 |
|
92,980 |
|
Broker Non-Votes: 8,377,859
Proposal 2 – Approval of
amendment to 2005 Incentive Stock Plan to increase the number of shares of common stock issuable thereunder to 8,333,333 and extend
the expiration date thereof to January 25, 2025.
For |
|
Against |
|
Abstain |
7,479,950 |
|
720,076 |
|
77,471 |
|
|
|
|
|
Broker Non-Votes: 8,377,859 |
|
|
|
|
Proposal 3- to ratify the appointment of Marcum LLP
as our independent registered public accounting firm for the fiscal year ending September 30, 2015.
For |
|
Against |
|
Abstain |
16,293,101 |
|
260,631 |
|
101,624 |
|
|
|
|
|
Broker Non-Votes: 0 |
|
|
|
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
Applied DNA Sciences, Inc. |
|
|
(Registrant) |
|
|
|
|
|
|
|
|
/s/ James A. Hayward |
|
|
James A. Hayward Chief Executive Officer |
|
|
|
Date:
June 18, 2015
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Applied DNA Sciences (NASDAQ:APDN)
Historical Stock Chart
From Apr 2023 to Apr 2024